Illinois Municipal Retirement Fund Grows Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Illinois Municipal Retirement Fund grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 11.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,146 shares of the company's stock after buying an additional 1,505 shares during the period. Illinois Municipal Retirement Fund's holdings in Krystal Biotech were worth $2,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter worth $40,000. Huntington National Bank lifted its holdings in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after purchasing an additional 283 shares during the last quarter. KBC Group NV boosted its position in shares of Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares during the period. Avanza Fonder AB acquired a new position in Krystal Biotech during the fourth quarter worth approximately $119,000. Finally, Blue Trust Inc. lifted its stake in Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on KRYS shares. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Friday. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $215.83.

Remove Ads

Krystal Biotech Price Performance

Shares of KRYS stock traded down $7.42 during trading hours on Monday, reaching $171.83. 331,825 shares of the company's stock were exchanged, compared to its average volume of 264,469. The company's 50 day moving average is $159.41 and its two-hundred day moving average is $175.08. The company has a market cap of $4.95 billion, a P/E ratio of 57.47 and a beta of 0.84. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech's revenue was up 116.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 earnings per share. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).